CRISPR Therapeutics(CRSP) - 2024 Q3 - Quarterly Results

Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results -CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland and Canada- -45 authorized treatment centers (ATCs) activated globally for CASGEVY and approximately 40 patients have had cells collected across all regions as of mid-October- -Two clinical trials are ongoing for next generation CAR T ...